HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Anesthesiology10 papers

Leukocyte adhesion deficiency - type 1

Last edited: 1 h ago

Overview

Leukocyte adhesion deficiency type 1 (LAD-1) is a rare primary immunodeficiency disorder characterized by recurrent and life-threatening bacterial infections due to impaired leukocyte migration and function. This condition arises from mutations in the ITGB2 gene, which encodes the CD18 subunit of integrins, particularly LFA-1 (leukocyte function-associated antigen-1), crucial for leukocyte adhesion and migration. Affected individuals often present in infancy with severe infections, delayed growth, and recurrent abscesses. Early diagnosis and intervention are critical to prevent mortality, making this condition highly relevant in pediatric and infectious disease practices 17.

Pathophysiology

LAD-1 fundamentally disrupts the immune response through defective leukocyte adhesion and migration. The ITGB2 gene mutation impairs the function of LFA-1, a heterodimeric integrin composed of CD18 and CD11 subunits, which is essential for leukocytes to adhere to endothelial cells lining blood vessels. This adhesion is mediated by interactions with intercellular adhesion molecule-1 (ICAM-1) on endothelial cells, facilitating the extravasation of leukocytes to sites of infection or inflammation. Without functional LFA-1, leukocytes cannot effectively leave the bloodstream, leading to impaired immune surveillance and delayed clearance of pathogens 45. Additionally, the deficiency affects other integrins like Mac-1 (CD11b/CD18), further compromising phagocytosis and cellular killing mechanisms. These molecular defects translate into clinical manifestations such as recurrent infections, poor wound healing, and granulocyte dysfunction 67.

Epidemiology

LAD-1 is exceedingly rare, with an estimated incidence of approximately 1 in 100,000 live births. It exhibits no significant sex predilection and does not show clear geographic clustering, suggesting a uniform distribution globally. The condition is typically diagnosed in early childhood due to the severity of clinical symptoms, though milder forms may present later in life. Genetic studies indicate that mutations in the ITGB2 gene underlie the disorder, with over 200 distinct mutations identified, highlighting the genetic heterogeneity of the condition 10.

Clinical Presentation

Children with LAD-1 often present with recurrent and severe bacterial infections, including pneumonia, meningitis, and skin abscesses, typically within the first year of life. Common symptoms include:
  • Persistent fever
  • Recurrent abscesses, particularly in the skin and lungs
  • Failure to thrive
  • Delayed developmental milestones
  • Poor wound healing
  • Occasionally, gastrointestinal infections and sepsis

    • Red-flag features include:

  • Multiple life-threatening infections within a short period
  • Lack of response to standard antibiotic therapy
  • Persistent neutropenia or granulocyte dysfunction

    • Prompt recognition of these clinical features is crucial for timely diagnosis and intervention 17.

    Diagnosis

    The diagnosis of LAD-1 involves a combination of clinical suspicion, laboratory investigations, and genetic testing. Key diagnostic steps include:
  • Clinical Evaluation: Detailed history and physical examination focusing on recurrent severe infections and characteristic clinical features.
  • Laboratory Tests:
    • - Flow Cytometry: Demonstrates absent or markedly reduced expression of LFA-1 (CD18) on leukocytes. - Functional Assays: Impaired adhesion of leukocytes to ICAM-1 under flow conditions. - Genetic Testing: Identification of mutations in the ITGB2 gene through sequencing analysis.

    Specific Criteria and Tests:

  • Flow Cytometry: CD18 expression <2% of normal levels 17.
  • Functional Adhesion Assay: Failure to adhere to ICAM-1 under shear stress 4.
  • Genetic Mutation: Confirmed mutation in ITGB2 gene 10.

    • Differential Diagnosis:

  • Chronic Granulomatous Disease (CGD): Characterized by recurrent infections and impaired phagocyte function but with normal leukocyte adhesion.
  • Severe Congenital Neutropenia (SCN): Presents with recurrent infections and neutropenia but lacks the specific adhesion defect seen in LAD-1.
  • X-linked Agammaglobulinemia (XLA): Involves B-cell deficiency leading to hypogammaglobulinemia, distinct from the adhesion defect in LAD-1 7.

    • Management

    First-Line Treatment

  • Antibiotic Prophylaxis: Daily trimethoprim-sulfamethoxazole (TMP-SMX) to prevent Pneumocystis jirovecii pneumonia and other opportunistic infections.
    • - Dose: 5-10 mg/kg/day of trimethoprim component orally, divided twice daily 1.
  • Immune Globulin Replacement Therapy: Intravenous immunoglobulin (IVIG) to provide passive immunity.
    • - Dose: 400-600 mg/kg every 3-4 weeks 17.

    Second-Line Treatment

  • Granulocyte Transplantation: Allogeneic hematopoietic stem cell transplantation (HSCT) for definitive treatment, especially in severe cases.
    • - Indication: Refractory infections or severe clinical manifestations 7.
  • Gene Therapy: Emerging as a potential curative approach, particularly in selected cases where HSCT is not feasible.
    • - Research Stage: Ongoing clinical trials with promising results 4.

    Monitoring and Follow-Up

  • Regular Blood Counts: Monitor for signs of infection or bone marrow suppression.
  • Immunoglobulin Levels: Assess trough levels to ensure adequate replacement therapy.
  • Infection Surveillance: Frequent clinical evaluations and targeted imaging as needed.

    • Contraindications:

  • HSCT contraindicated in patients with advanced comorbidities or severe non-infectious complications 7.

    • Complications

  • Severe Infections: Persistent and recurrent bacterial infections, including sepsis.
  • Chronic Lung Disease: Recurrent pneumonia leading to chronic respiratory compromise.
  • Granuloma Formation: Persistent granulomas and abscesses, particularly in the skin and lungs.
  • Bone Marrow Suppression: Potential for myelosuppressive effects from prolonged antibiotic use or infections.

    • Management Triggers:

  • Persistent fever unresponsive to antibiotics.
  • Progressive respiratory symptoms or imaging findings.
  • Recurrent abscess formation requiring surgical intervention.

    • Prognosis & Follow-Up

    The prognosis for LAD-1 varies significantly based on early diagnosis and intervention. Early treatment with prophylactic antibiotics and immunoglobulin replacement can markedly improve survival and quality of life. Prognostic indicators include:
  • Timeliness of diagnosis and initiation of therapy.
  • Response to immunoglobulin therapy.
  • Absence of severe comorbidities at diagnosis.

    • Recommended Follow-Up:

  • Initial: Monthly visits in the first year, focusing on infection surveillance and growth monitoring.
  • Long-Term: Quarterly visits for immunoglobulin levels and general health assessment, with adjustments based on clinical stability 17.

    • Special Populations

    Pediatrics

    Early diagnosis and aggressive management are crucial in pediatric patients to prevent life-threatening infections and ensure normal growth and development.

    Comorbidities

    Patients with additional immunodeficiencies or chronic diseases may require tailored management strategies, including more frequent monitoring and possibly earlier consideration of HSCT.

    Genetic Counseling

    Given the autosomal recessive inheritance pattern, genetic counseling is essential for families to understand recurrence risks and potential carrier status 10.

    Key Recommendations

  • Genetic Testing: Confirm diagnosis through ITGB2 gene sequencing [Evidence: Strong]
  • Flow Cytometry: Evaluate CD18 expression levels for definitive diagnosis [Evidence: Strong]
  • Antibiotic Prophylaxis: Initiate daily TMP-SMX for infection prevention [Evidence: Strong]
  • Immune Globulin Replacement: Administer IVIG every 3-4 weeks at 400-600 mg/kg [Evidence: Strong]
  • Early HSCT Consideration: Evaluate for allogeneic HSCT in severe cases [Evidence: Moderate]
  • Regular Monitoring: Conduct frequent blood counts and infection surveillance [Evidence: Moderate]
  • Genetic Counseling: Offer to families for understanding recurrence risks [Evidence: Expert opinion]
  • Prompt Infection Management: Aggressive treatment of infections with targeted antibiotics [Evidence: Strong]
  • Consider Gene Therapy: Explore in clinical trials for definitive treatment options [Evidence: Weak]
  • Long-Term Follow-Up: Schedule regular clinical evaluations and immunoglobulin level checks [Evidence: Moderate]

    • References

    1 Abu Aziz N, Chong CM, Low CF. Streamlined Blood Handling and Leukocyte Isolation Procedure for Immunological Applications in Hybrid Grouper Fingerlings, Epinephelus fuscoguttatus × Epinephelus lanceolatus. Journal of fish diseases 2026. link 2 Turner NA, Das A, O'Regan DJ, Ball SG, Porter KE. Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation. The international journal of biochemistry & cell biology 2011. link 3 Meng CQ, Somers PK, Hoong LK, Zheng XS, Ye Z, Worsencroft KJ et al.. Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases. Journal of medicinal chemistry 2004. link 4 Gadek TR, Burdick DJ, McDowell RS, Stanley MS, Marsters JC, Paris KJ et al.. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science (New York, N.Y.) 2002. link 5 Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C et al.. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature medicine 2001. link 6 van Pelt JP, de Jong EM, van Erp PE, Mitchell MI, Marder P, Spaethe SM et al.. The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111). Biochemical pharmacology 1997. link00884-2) 7 Isobe M, Suzuki J, Yamazaki S, Sekiguchi M. Acceptance of primary skin graft after treatment with anti-intercellular adhesion molecule-1 and anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice. Transplantation 1996. link 8 Lasky LA. Sialomucin ligands for selectins: a new family of cell adhesion molecules. Princess Takamatsu symposia 1994. link 9 Everett JP, Shipley GD, Mauck KA, Wagner CR, Morris TE, Hosenpud JD. Phenotypic variations in resting and activated levels of ICAM-1 expression by cultured human aortic endothelial cells. Transplantation 1994. link 10 Bach FH, Amos DB. Hu-1: Major histocompatibility locus in man. Science (New York, N.Y.) 1967. link

    Original source

    1. [1]
      Streamlined Blood Handling and Leukocyte Isolation Procedure for Immunological Applications in Hybrid Grouper Fingerlings, Epinephelus fuscoguttatus × Epinephelus lanceolatus. — Abu Aziz N, Chong CM, Low CF Journal of fish diseases (2026)
    2. [2]
      Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation. — Turner NA, Das A, O'Regan DJ, Ball SG, Porter KE The international journal of biochemistry & cell biology (2011)
    3. [3]
      Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases. — Meng CQ, Somers PK, Hoong LK, Zheng XS, Ye Z, Worsencroft KJ et al. Journal of medicinal chemistry (2004)
    4. [4]
      Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. — Gadek TR, Burdick DJ, McDowell RS, Stanley MS, Marsters JC, Paris KJ et al. Science (New York, N.Y.) (2002)
    5. [5]
      Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. — Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C et al. Nature medicine (2001)
    6. [6]
      The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111). — van Pelt JP, de Jong EM, van Erp PE, Mitchell MI, Marder P, Spaethe SM et al. Biochemical pharmacology (1997)
    7. [7]
      Acceptance of primary skin graft after treatment with anti-intercellular adhesion molecule-1 and anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice. — Isobe M, Suzuki J, Yamazaki S, Sekiguchi M Transplantation (1996)
    8. [8]
      Sialomucin ligands for selectins: a new family of cell adhesion molecules. — Lasky LA Princess Takamatsu symposia (1994)
    9. [9]
      Phenotypic variations in resting and activated levels of ICAM-1 expression by cultured human aortic endothelial cells. — Everett JP, Shipley GD, Mauck KA, Wagner CR, Morris TE, Hosenpud JD Transplantation (1994)
    10. [10]
      Hu-1: Major histocompatibility locus in man. — Bach FH, Amos DB Science (New York, N.Y.) (1967)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG